Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease.
In the present studies, the effect of paeoniflorin (PF), one of the main compounds extracted from Paeoniae radix, in alleviating the neurological impairment following unilateral striatal 6-hydroxydopamine (6-OHDA) lesion was examined in Sprague-Dawley rats. Sub-chronic PF (2.5, 5 and 10 mg/kg, s.c., twice daily for 11 days) administration dose-dependently reduced apomorphine (APO)-induced rotation, suggesting that PF had an ameliorative effect on the 6-OHDA-induced neurological impairment. Notably, PF had no direct action on dopamine D(1) receptor or dopamine D(2) receptor indicated by the competitive binding experiments. These results suggest that PF, an active component of Paeoniae radix, might provide an opportunity to introduce a non-dopaminergic management of Parkinson's disease.
Liu
Da-Zhi
DZ
Department of Pharmacology II, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.
Zhu
Jun
J
Jin
Dao-Zhong
DZ
Zhang
Li-Min
LM
Ji
Xin-Quan
XQ
Ye
Yang
Y
Tang
Chun-Ping
CP
Zhu
Xing-Zu
XZ
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001552:Benzazepines / Q000378:metabolism; D001565:Benzoates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001667:Binding, Competitive / Q000187:drug effects; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000378:metabolism; D005960:Glucosides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D006892:Hydroxydopamines; D066298:In Vitro Techniques; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D008845:Microinjections; D039821:Monoterpenes; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology*; D020891:Raclopride / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013239:Stereotyped Behavior / Q000187:drug effects; D006027:Glycosides
D001058:Apomorphine; D001552:Benzazepines; D001565:Benzoates; D001952:Bridged-Ring Compounds; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D005960:Glucosides; D006892:Hydroxydopamines; D039821:Monoterpenes; D020891:Raclopride; C015423:peoniflorin; D006027:Glycosides